EGFR and lung adenocarcinoma: In EGFR-driven lung adenocarcinoma (LUAD), tumor-associated alveolar macrophages (TA-AMs) can reduce EGFR phosphorylation and inhibit LUAD progression by enhancing GM-CSF-PPARγ signaling and suppressing PPARγ-driven signaling to inhibit cholesterol flux toward tumor cells.